Dr. Allen’s Thermobalancing Devices In The Press

Read about what other people say about Dr. Allen’s therapeutic Thermobalancing devices, and choose the best treatment option for you:

Promoting health and well-being through the application of socialist principles

Improving Men’s Life Quality Naturally With Innovative Thermobalancing Therapy When Affected By BPH

Britons Suffer Multiple Diseases, Thermobalancing Therapy May Help

Dr Allen’s Therapeutic Devices Should be Implemented in the Healthcare System for the Treatment of Chronic Noncancerous Prostate and Kidney Diseases Saving People’s Well-Being and Money

Thermobalancing therapy in Primary Care

Thermobalancing therapy should be used in Primary Care, Oct 2018.

World Scientific News, October 2018

Thermobalancing Therapy Offers Israelis New Prostate Treatment Options

International Physiotherapy Conference, London – Aug 2018

Aug 6, 2018 – New safe therapy to reverse prostate enlargement: Thermobalancing

Thermobalancing therapy vs drugs
Thermobalancing therapy vs BPH drugs and in October 2018 – treatment of benign prostatic hyperplasia (BPH), chronic prostatitis and kidney stone disease should be performed by physicians. 

Sept 2018, CBN, Thermobalancing therapy vs ESWL and PCNL!

Clinical results now confirmed:

A study involving 124 men with BPH, to whom the therapeutic device was administered exclusively as a mono-therapy, has confirmed the effectiveness and safety of Thermobalancing therapy.

Breaking News about Prostate treatmentThe Vascular Factor Plays the Main Role in the Cause of Pain in Men with Chronic Prostatitis and Chronic Pelvic Pain Syndrome: The Results of Clinical Trial on Thermobalancing Therapy.

Kidney stone disease

Kidney stones disease must be be treated in safe with new Thermobalancing therapy in the first place

Thermobalancing therapy should be the first-line treatment for kidney stone disease. The common standard treatments, such as Extracorporeal Shock Wave Lithotripsy. (ESWL) and Percutaneous Nephrolithotomy (PCNL) are risky.